Full-Time
Proposals Development Associate
Icon
10,001+ employees
Consulting and development services for pharmaceuticals
No salary listed
Entry, Junior
Reading, UK + 1 more
More locations: Dublin, Ireland
In Person
- Bachelor's degree in life sciences, business administration, or a related field.
- Experience in proposal development is desirable in clinical research, or related roles within the pharmaceutical, biotechnology, or CRO industry ranging from labs through to late phase clinical development.
- Strong attention to detail and organizational skills, with the ability to manage multiple tasks and deadlines simultaneously.
- Excellent written and verbal communication skills, with the ability to convey complex information in a clear and concise manner.
- Proficiency in Microsoft Office suite (Word, Excel, PowerPoint) and familiarity with proposal management software or CRM systems is a plus.
- Leading the preparation and development of client proposals, including cost estimates, timelines, and scope of work documents.
- Collaborating closely with cross-functional teams, including clinical operations, project management, and finance, to gather necessary information and ensure proposal accuracy and completeness.
- Conducting comprehensive research and analysis to understand client requirements, competitive landscape, and market trends, informing proposal development strategies.
- Managing proposal process workflows, including tracking proposal status, coordinating review cycles, and ensuring adherence to internal processes and timelines.
- Maintaining proposal templates, databases, and other tools to support efficient and effective proposal development and management.
- Experience in proposal development is desirable in clinical research, or related roles within the pharmaceutical, biotechnology, or CRO industry ranging from labs through to late phase clinical development.
Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon leverages a global network of experts who have experience across various therapeutic areas. This extensive expertise allows them to tailor their solutions to meet the specific needs of their clients, setting them apart from competitors who may not offer the same level of specialized support. The primary goal of Icon is to support the development of life-saving and life-improving products efficiently and effectively.
Company Size
10,001+
Company Stage
IPO
Headquarters
Ireland
Founded
1990
Simplify's Take
What believers are saying
- Increased use of AI accelerates clinical trial participant identification.
- Partnership with Mural Health enhances trial participant and site experience.
- Centre for Obesity expedites obesity-related clinical trials.
What critics are saying
- Complexity of multi-indication trials may lead to inefficiencies.
- Securities fraud lawsuit could cause financial and reputational damage.
- Underutilization of biomarkers may hinder optimization of neurodegenerative trials.
What makes Icon unique
- ICON offers a global network of offices in 53 countries.
- The company focuses on reducing time to market, cost, and increasing quality.
- ICON has extensive experience in a broad range of therapeutic areas.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Retirement Plan
Mental Health Support
Life Insurance
Flexible Work Hours
Company News
At Bio€quity Europe 2025, the premier investor conference for European biopharma, ICON was proud to contribute to the conversation shaping the future of early-stage innovation.
Alongside the whitepaper, ICON has launched their new Centre for Obesity that delivers expertise and market intelligence with a ready-to-deploy infrastructure of 100 sites and an in-development database of 10,000 pre-screened patients across the breadth of comorbidities related to obesity.
Dublin, Ireland – 7 May – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic RD for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% of respondents) are pursuing multi-indication approaches in their obesity-related research. However, the survey results also suggest that sponsors may underestimate the complexity of these strategies - particularly when selecting inclusion criteria and endpoints - which can lead to inefficiencies in the clinical development process
After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.
ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.